|Bid||6.01 x 900|
|Ask||8.00 x 800|
|Day's Range||6.57 - 7.20|
|52 Week Range||5.51 - 17.71|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||15.69|
|Earnings Date||Feb 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jan 31, 2019|
|1y Target Est||9.00|
In order to help expedite such development, Meridian is pleased to provide from stock its specialized enzyme formulations to manufacturers of a COVID-19 molecular detection assay at no cost for the purpose of initial testing and evaluation. Following the successful development of a COVID-19 detection assay or kit, it is Meridian’s commitment to continue to manufacture and supply its propriety formulations at commercial scale in order to meet the global demand.
CINCINNATI, March 16, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced.
Investors who take an interest in Meridian Bioscience, Inc. (NASDAQ:VIVO) should definitely note that the President...
To the annoyance of some shareholders, Meridian Bioscience (NASDAQ:VIVO) shares are down a considerable 33% in the...
The U.S. stock market rallied on Wednesday, with the Dow Jones industrial average shooting up nearly 1,200 points following a Super Tuesday surge for Democratic presidential candidate Joe Biden. Shares in Cincinnati-based companies rode that wave.
CINCINNATI, Feb. 26, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), following the extremely successful launch of the Lyo-Ready qPCR mixes, is proud to introduce today its.
Greater Cincinnati stocks took a beating on Monday as the stock market plummeted in the wake of an escalation in coronavirus cases.
Today we'll evaluate Meridian Bioscience, Inc. (NASDAQ:VIVO) to determine whether it could have potential as an...
Meridian Bioscience Inc. disclosed Feb. 19 that the Newtown-based maker of diagnostic test kits plans to acquire another public company, Exalenz Bioscience Ltd. of Israel, for about $49 million in cash. Meridian (Nasdaq: VIVO) cited a desire to add Exalenz’s flagship BreathID Breath Test Systems platform for the detection of Helicobacter pylori, a bacteria often associated with peptic ulcers and gastric cancer. Meridian will discuss the financial impact of the transaction during its fiscal second quarter earnings call in May. The Israeli company’s shares are traded on the Tel Aviv Stock Exchange, and the acquisition is subject to Exalenz shareholder approval.
Meridian Bioscience, Inc. (VIVO) and Exalenz Bioscience Ltd. (TASE:EXEN) announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for ₪6.10 per share in cash with an implied transaction value of approximately $49 million. With this acquisition, Meridian will be adding Exalenz’s flagship BreathID® Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori, often associated with peptic ulcers and gastric cancer.
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 66.67% and -2.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
CINCINNATI, Feb. 07, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019. First Quarter Fiscal.
Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A nearly weeklong rally for vaccine and diagnostics developers looking to capitalize on the coronavirus outbreak ended on Tuesday.
Over the last few days, the company has seen significant demand for one of its products, which enables laboratories in China to develop fast and accurate screening assays for the deadly new strain of virus.
Meridian Bioscience, Inc. (VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not been previously identified in humans. This new virus has already spread to other parts of mainland China and several other countries and health authorities around the world are taking action to prevent a global epidemic. The World Health Organization (WHO) has provided interim guidance to laboratories and stakeholders involved in laboratory testing of patients who meet the definition of suspected case of pneumonia associated with 2019-nCoV.
CINCINNATI, Jan. 23, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of a High-Specificity Pfu HS Mix that not only provides high-fidelity.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
CINCINNATI, Jan. 15, 2020 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter 2020.
In this article we are going to estimate the intrinsic value of Meridian Bioscience, Inc. (NASDAQ:VIVO) by taking the...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
A hearing has been scheduled in federal court in Cincinnati so a judge can determine whether to approve a proposed $2.1 million settlement in a class-action lawsuit filed against Meridian Bioscience following dips in the firm’s stock price in 2017.